Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease Endpoints News
News Source : Endpoints News
News Summary
- At $65 a share, Vertex will pay a substantial premium for Alpine, whose stock $ALPN closed Tuesday at $37
- 57
- Alpine Immune Sciences and its experimental drug povetacicept are being sold
Reshma Kewalramani is putting Vertexs $10 billionplus balance sheet to work.On Wednesday, the biotech announced it would pay $4.9 billion for Alpine Immune Sciences and its experim [+579 chars]